These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 12687928)

  • 1. [Usefulness of soluble ICAM-1 measurements for the evaluation of the disease activity and efficiency of therapy in patients with infiltrative Graves' ophthalmopathy].
    Kulig G; Pilarska K; Kulig J; Krzyzanowska-Swiniarska B; Robaczyk M; Baraniak A
    Pol Arch Med Wewn; 2002 Dec; 108(6):1161-9. PubMed ID: 12687928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Behavior of soluble intercellular adhesion molecule-1 and endothelial-leukocyte adhesion molecule-1 concentrations in patients with Graves' disease with or without ophthalmopathy and in patients with toxic adenoma.
    De Bellis A; Bizzarro A; Gattoni A; Romano C; Di Martino S; Sinisi AA; Abbadessa S; Bellastella A
    J Clin Endocrinol Metab; 1995 Jul; 80(7):2118-21. PubMed ID: 7541801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble intercellular adhesion molecule-1 (sICAM-1) concentrations in Graves' disease patients followed up for development of ophthalmopathy.
    De Bellis A; Di Martino S; Fiordelisi F; Muccitelli VI; Sinisi AA; Abbate GF; Gargano D; Bellastella A; Bizzarro A
    J Clin Endocrinol Metab; 1998 Apr; 83(4):1222-5. PubMed ID: 9543145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble intercellular adhesion molecule-1 (sICAM-1) in sera of patients with Graves' ophthalmopathy and thyroid diseases.
    Heufelder AE; Bahn RS
    Clin Exp Immunol; 1993 May; 92(2):296-302. PubMed ID: 8097976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prognostic role of adhesion molecules sELAM-1 and sICAM-1 in glucocorticoid therapy of active ophthalmopathy].
    Modelska-Ziółkiewicz A; Gembicki M; Bednarek J; Sowiński J
    Pol Arch Med Wewn; 2003 May; 109(5):469-75. PubMed ID: 14768175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Smoking and disease severity are independent determinants of serum adhesion molecule levels in Graves' ophthalmopathy.
    Wakelkamp IM; Gerding MN; van der Meer JW; Prummel MF; Wiersinga WM
    Clin Exp Immunol; 2002 Feb; 127(2):316-20. PubMed ID: 11876756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Soluble forms of adhesion molecules sELAM-1 and sICAM-1 in Graves disease and toxic nodular goiter].
    Modelska-Ziółkiewicz A; Gembicki M; Sowiński J
    Pol Arch Med Wewn; 2003 May; 109(5):463-8. PubMed ID: 14768174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble intercellular adhesion molecule-1 (sICAM-1) in Graves' disease.
    Balázs C; Kiss E
    Acta Microbiol Immunol Hung; 1994; 41(4):451-6. PubMed ID: 7866729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble intercellular adhesion molecule-1 concentrations in patients with subacute thyroiditis and in patients with Graves' disease with or without ophthalmopathy.
    Ozata M; Bolu E; Sengül A; Altinsoy HI; Turan M; Corakci A; Hacibektasoglu A; Gundogan MA
    Endocr J; 1996 Oct; 43(5):517-25. PubMed ID: 8980891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum antibodies to collagen XIII: a further good marker of active Graves' ophthalmopathy.
    De Bellis A; Sansone D; Coronella C; Conte M; Iorio S; Perrino S; Battaglia M; Bellastella G; Wall JR; Bellastella A; Bizzarro A
    Clin Endocrinol (Oxf); 2005 Jan; 62(1):24-9. PubMed ID: 15638866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intercellular adhesion molecule-1 (ICAM-1) in the sera of patients with Graves' disease: correlation with disease activity and treatment status.
    Fukazawa H; Yoshida K; Kaise N; Kiso Y; Sayama N; Mori K; Kikuchi K; Aizawa Y; Rikimaru A; Abe K
    Thyroid; 1995 Oct; 5(5):373-7. PubMed ID: 8563475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The blood concentration of intercellular adhesion molecule-1 (sICAM-1) and vascular cell adhesion molecule-1 (sVCAM-1) in patients with active thyroid-associated orbitopathy before and after methylprednisolone treatment.
    Nowak M; Wielkoszyński T; Kos-Kudła B; Marek B; Karpe J; Kajdaniuk D; Siemińska L; Głogowska-Szelag J; Foltyn W; Strzelczyk J; Nowak K
    Endokrynol Pol; 2007; 58(6):487-91. PubMed ID: 18205104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.
    Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D
    J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Assessment of soluble E selectin levels in patients with Graves' disease and thyroid orbitopathy].
    Kulig G; Pilarska K; Kulig J; Robaczyk M; Gromniak E
    Przegl Lek; 2004; 61(12):1314-8. PubMed ID: 15850320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal study of soluble intercellular adhesion molecule-1 (ICAM-1) in sera of patients with Graves' disease.
    Sonnet E; Massart C; Gibassier J; Allannic H; Maugendre D
    J Endocrinol Invest; 1999 Jun; 22(6):430-5. PubMed ID: 10435852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum L-selectin and ICAM-1 in patients with Graves' ophthalmopathy during treatment with corticosteroids.
    Myśliwiec J; Kretowski A; Szelachowska M; Topolska J; Mikita A; Kinalska I
    Immunol Lett; 2001 Oct; 78(3):123-6. PubMed ID: 11578685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of octreotide treatment on Graves' ophthalmopathy and circulating sICAM-1 levels.
    Ozata M; Bolu E; Sengul A; Tasar M; Beyhan Z; Corakci A; Gundogan MA
    Thyroid; 1996 Aug; 6(4):283-8. PubMed ID: 8875747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Magnetic resonance imaging and soluble forms of adhesion molecules: sICAM and sVCAM in assessing the activity of thyroid orbitopathy].
    Kulig G; Pilarska K; Kulig J; Krzyzanowska-Swiniarska B; Andrysiak-Mamos E; Robaczyk M
    Pol Arch Med Wewn; 2004 Feb; 111(2):161-9. PubMed ID: 15230228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Concentrations of soluble vascular cell adhesion molecule-1 (sVCAM-1) in patients witt Graves' disease and thyroid associated orbitopathy].
    Kulig G; Pilarska K; Kulig J
    Przegl Lek; 2004; 61(12):1319-24. PubMed ID: 15850321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum levels of soluble TNFalpha receptors (sTNFR1 and sTNFR2) during corticosteroid treatment in patients with Graves' ophthalmopathy.
    Myśliwiec J; Kretowski A; Stepień A; Kinalska I
    Immunol Invest; 2004 Feb; 33(1):61-8. PubMed ID: 15015833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.